erlotinib hydrochloride has been researched along with edoxaban in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (edoxaban) | Trials (edoxaban) | Recent Studies (post-2010) (edoxaban) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 910 | 178 | 873 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | edoxaban (IC50) |
|---|---|---|---|
| Coagulation factor X | Homo sapiens (human) | 0.0034 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujitaka, K; Hamai, K; Hongoh, M; Hotta, T; Ishihara, N; Ishikawa, N; Isobe, T; Kobayashi, M; Kubota, T; Nakamura, A; Nishimura, N; Sugisaka, J; Tanino, A; Tsubata, Y; Yamasaki, M | 1 |
1 other study(ies) available for erlotinib hydrochloride and edoxaban
| Article | Year |
|---|---|
Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Factor Xa Inhibitors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyridines; Thiazoles; Venous Thromboembolism | 2021 |